• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Evaluating Immunogenicity Risk Due to Host Cell Protein Impurities in Antibody-Based Biotherapeutics

Evaluating Immunogenicity Risk Due to Host Cell Protein Impurities in Antibody-Based Biotherapeutics

by Sarah Moniz | Dec 22, 2017

Improved Personalized Vaccine and Adoptive Cell Transfer Immunotherapy Design by Immunoinformatic Analysis of Cancer Neo-epitopes

Improved Personalized Vaccine and Adoptive Cell Transfer Immunotherapy Design by Immunoinformatic Analysis of Cancer Neo-epitopes

by Adam | Oct 21, 2016

High-Value T Cell Epitope Selection for Mutanome-Directed Cancer Immunotherapy Using an Innovative Cancer Neo-Epitope Classification System

High-Value T Cell Epitope Selection for Mutanome-Directed Cancer Immunotherapy Using an Innovative Cancer Neo-Epitope Classification System

by Adam | Oct 21, 2016

Immunogenicity Analysis of Chinese Hamster Ovary (CHO) Host Cell Protein Contaminants in Therapeutic Protein Formulations

Immunogenicity Analysis of Chinese Hamster Ovary (CHO) Host Cell Protein Contaminants in Therapeutic Protein Formulations

by Adam | Oct 21, 2016

The ISPRI Toolkit Rapidly Screens Biologic Product Candidates for Immunogenic Potential Driven by T cell Epitope Content and Foreignness

The ISPRI Toolkit Rapidly Screens Biologic Product Candidates for Immunogenic Potential Driven by T cell Epitope Content and Foreignness

by Adam | Oct 21, 2016

« Older Entries

Recent Posts

  • Tregs, Epitopes, and the Future of Immune Tolerance
  • The Platinum Vaccine & Change is Good!
  • EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO
  • Smarter Tools, Safer Therapies: Supporting the FDA’s Roadmap with in silico Immunogenicity Assessment
  • The Amsterdam Immunogenicity & Tolerance Seminar: 2025

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CMO, Dr. Annie De Groot.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.